{"filings":[{"id":90565,"accession_number":"0001140361-26-019538","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 net loss widens to $3.5M; revenue falls to $6.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $3.5M vs $5.8M YoY; total revenue $6.2M vs $7.0M.","Operating loss $(5.3)M; net loss $(3.5)M or $(0.05) diluted EPS.","Expects $13M oral TPOXX delivery to Asia Pacific customer in Q2 and $26M IV TPOXX to US SNS by end of Q3 2026.","Signed exclusive license with Hikma MENA for TPOXX commercialization in MENA region in March 2026.","Declared special cash dividend $0.60/share in March 2026, paid April 23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":6242580.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100199,"accession_number":"0001140361-26-011361","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SIGA declares special $0.60/share dividend payable April 23","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special one-time cash dividend of $0.60 per common share declared.","Record date for dividend is April 7, 2026.","Dividend payable on April 23, 2026.","Announced on March 26, 2026 via press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100198,"accession_number":"0001140361-26-008782","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA 2025 product revenue $88M, down 34% YoY; net income $23.3M vs $59.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues of $88M in 2025, down from $133M in 2024; total revenues $94.6M.","Net income of $23.3M ($0.32 diluted EPS) vs $59.2M ($0.82) in 2024.","Q4 product sales fell to $2.2M from $79.8M; operating loss of $9.5M.","Received $13M international order for oral TPOXX in Jan 2026; delivery expected in 2026.","BARDA 19C contract added $27M in development funding for pediatric program and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116533,"accession_number":"0001140361-25-040775","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports Q3 2025 net loss of $6.4M on $2.6M revenue, down from $1.3M income YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 product sales fell to $0.9M from $8.9M YoY; total revenue $2.6M vs $10.0M.","Net loss of $6.4M ($0.09 diluted loss per share) vs net income of $1.3M ($0.02) in Q3 2024.","Nine-month 2025 product revenues $85.8M, net income $28.7M ($0.40 EPS) vs $53.5M and $13.5M ($0.19) in 2024.","Year-to-date $53M oral TPOXX and $26M IV TPOXX delivered to U.S. SNS; $6M oral to international customer.","Special dividend of $0.60/share paid May 2025; BARDA contract added $27M development funding in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":90780818.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132986,"accession_number":"0001140361-25-028821","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales","Net income of $35.5M ($0.49 diluted EPS) versus $1.8M ($0.03) in Q2 2024; operating income $45.7M vs $1.1M","Gain on sale of aviation consultancy business to WMES joint venture of $43.0M in Q2 2025","BARDA 19C contract modified to add $27M in development funding during Q2, including $13M for pediatric program and $14M for manufacturing","Special cash dividend of $0.60 per share declared April 8, paid May 15, 2025; portfolio utilization improved to 88.3%"],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":88160818.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149542,"accession_number":"0001140361-25-022316","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"SIGA shareholders elect board, ratify auditor, approve officer liability amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; highest vote total 52.1M for John M. Keane; lowest 47.8M for Joseph W. Marshall.","Ratification of PricewaterhouseCoopers as auditor: 62.4M for, 1.6M against, 22.8K abstain.","Amendment to limit officer liability approved: 48.7M for, 4.3M against, 18.5K abstain.","Bylaws amended to designate Delaware Chancery Court as exclusive forum for state law claims and federal district courts for Securities Act claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149541,"accession_number":"0001140361-25-017954","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 2025 net loss $0.4M, revenue $7.0M; special dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 total revenues $7.0M (down 72% YoY); net loss $0.4M ($0.01 EPS) vs net income $10.3M ($0.14 EPS) in Q1 2024.","Outstanding SNS orders $94M as of March 31, 2025; expect delivery of $70M by end of Q3 2025, remainder in 2026.","Received $26M IV TPOXX order from U.S. Govt in March; contract modification added $14M for manufacturing support.","International sale of ~$6M in Q1; TPOXX received regulatory approval in Japan (as TEPOXX) in January 2025.","Special cash dividend of $0.60/share declared on April 8, payable May 15, 2025 to holders of record April 29."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":7040815.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149540,"accession_number":"0001140361-25-012708","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SIGA declares special one-time dividend of $0.60/share payable May 15, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special one-time cash dividend of $0.60 per share declared on April 8, 2025.","Dividend payable on May 15, 2025 to holders of record on April 29, 2025.","No other significant news or financial results disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168614,"accession_number":"0001140361-25-009163","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies appoints General John M. Keane to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gen. Keane appointed effective March 17, 2025; term expires at next annual meeting.","Granted fully vested options for 25,000 shares at $5.63 (closing price on appointment date).","Annual retainer of $45,000 (prorated) paid quarterly in arrears.","Board determined Keane meets Nasdaq independence requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168613,"accession_number":"0001140361-25-008092","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA FY2024 net income $59.2M ($0.82 EPS); product sales $133M, up 2% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales were $133M in 2024 vs $130.7M in 2023, including $100M to US SNS.","Net income $59.2M ($0.82 diluted EPS) vs $68.1M ($0.95) in 2023; operating income $70M.","Q4 product sales $79.8M, down from $115.7M in Q4 2023; Q4 net income $45.7M ($0.63 EPS).","Company has ~$70M of outstanding procurement orders entering 2025.","TPOXX received Japanese approval in Jan 2025; first African sale to Morocco in Oct 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185727,"accession_number":"0001140361-24-049534","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"SIGA Technologies amends bylaws to update stockholder nomination procedures and proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended and restated bylaws effective Dec 10, 2024.","Updates advance notice provisions for stockholder nominations, incorporating SEC universal proxy rules (Rule 14a-19).","Stockholder list provisions updated to reflect Delaware law amendments.","New rule: stockholder soliciting proxies must use a proxy card color other than white.","Additional ministerial and clarifying changes made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185726,"accession_number":"0001140361-24-048907","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.","Enrollment halted in all study arms including open-label for severe patients; data analysis ongoing for secondary endpoints.","Safety profile affirmed as comparable to placebo, consistent with prior studies over 15 years.","CEO stated ~75% of randomized patients received drug >5 days after symptom onset; early treatment may offer benefit.","Company expects three ongoing trials (UNITY, Platinum-CAN, EPOXI) to yield similar results given design parallels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185725,"accession_number":"0001140361-24-045654","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.","Net income of $1.3M ($0.02 diluted EPS) vs net loss of $0.4M in Q3 2023.","Received $122M in procurement orders, including $112.5M from BARDA for oral TPOXX to the SNS.","Special cash dividend of $0.60/share paid April 2024, up $0.15 from prior year.","Exclusive license from Vanderbilt for preclinical monoclonal antibodies targeting orthopoxviruses."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":57250527.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185724,"accession_number":"0001140361-24-042883","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SIGA shifts CFO and CSO comp to equity-heavy mix; bonus targets cut from 100% to 50% of salary by 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Luckshire and CSO Hruby target annual bonus drops to 75% of base salary in 2025, then 50% from 2026 onward.","Equity grants rise to 50% of base salary in 2025, 75% in 2026, then 100% from 2027 onward.","Luckshire gets enhanced change-of-control severance: 2x (base + target bonus) plus 18 months COBRA.","Amendments effective October 1, 2024; 2024 annual bonus target remains at 100% of base salary.","Changes aim to better align officer incentives with long-term stockholder interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202294,"accession_number":"0001140361-24-041654","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies terminates EVP and CMO Dr. Jay Varma effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Varma terminated as EVP and Chief Medical Officer on September 23, 2024.","Termination was other than for cause, effective immediately.","His service on the Board of Directors automatically ended.","No replacement for Dr. Varma has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202293,"accession_number":"0001140361-24-041564","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SIGA Technologies CMO and Board Member Jay Varma begins indefinite leave","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay K. Varma commenced indefinite leave as EVP, Chief Medical Officer and board member on Sept 19, 2024.","No replacement or interim appointment announced for either the CMO role or board seat.","Company has not disclosed the reason for leave or expected duration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202292,"accession_number":"0001140361-24-037428","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.","Tecovirimat showed clinical benefit vs. placebo in patients treated ≤7 days from symptom onset and those with ≥100 lesions.","Safety profile comparable to placebo; consistent with prior studies over 15 years.","Four additional randomized trials (STOMP, UNITY, Platinum-CAN, EPOXI) are ongoing.","Trial hospitalized all patients, which may have reduced measured benefit vs. real-world settings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202291,"accession_number":"0001140361-24-035316","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q2 product sales $20.7M, net income $1.8M; receives $113M U.S. order in July","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $20.7M in Q2 (vs $1.3M prior year); total revenues $21.8M; net income $1.8M or $0.03 diluted EPS.","Received $113M procurement order from U.S. government for oral TPOXX in July 2024 under BARDA contract.","Delivered $18M of IV TPOXX to U.S. SNS in Q2; $3M oral TPOXX to new ASEAN customer.","Paid special cash dividend of $0.60 per share on April 11, 2024, up $0.15 from prior year.","Amendment with Meridian gives SIGA control over international promotion of oral TPOXX effective June 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":47240746.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202290,"accession_number":"0001140361-24-033536","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SIGA receives $113M US government procurement order for oral TPOXX","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. HHS exercised procurement option for ~$113M of oral TPOXX treatment courses under current contract.","Order builds on 2023 orders from U.S. government and 15 international customers for orthopoxvirus preparedness.","Project funded by BARDA and Strategic National Stockpile under contract 75A50118C00019.","CEO Diem Nguyen says order supports public health and shareholder returns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218390,"accession_number":"0001140361-24-030011","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SIGA stockholders elect nine directors and ratify PwC as auditor for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["90.04% of shares represented at June 11, 2024 annual meeting.","All nine director nominees elected; Diem Nguyen received highest 'for' votes (50,834,176).","Ratification of PwC as auditor: 61,952,614 for, 1,879,362 against, 212,356 abstain.","Broker non-votes on director elections: 13,008,032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218389,"accession_number":"0001140361-24-024697","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.","Operating income $11.3M vs loss $2.1M YoY; net income $10.3M vs loss $0.9M; diluted EPS $0.14 vs ($0.01).","Partner Japan Biotechno Pharma filed NDA for tecovirimat in Japan for smallpox, mpox, etc. on April 11, 2024.","Amendment to Meridian agreement: SIGA takes over international promotion of oral TPOXX effective June 1, 2024.","Special cash dividend of $0.60 per share declared March 12, paid April 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":25429855.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218388,"accession_number":"0001140361-24-016900","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"SIGA assumes primary responsibility for oral TPOXX promotion; Meridian retains limited rights in EU/UK/AU/JP/CH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Promotion Agreement effective June 1, 2024; SIGA takes over global advertising, promotion and sale of oral TPOXX.","Meridian retains non-exclusive rights only in European Economic Area, Australia, Japan, Switzerland and the UK.","Meridian receives reduced promotion fee: high single-digit percentage of collected proceeds from Territory sales.","Agreement has fixed term expiring May 31, 2026, with no automatic renewal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238315,"accession_number":"0001140361-24-012801","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SIGA Technologies reports 2023 product sales of $131M, pre-tax operating income $84M; declares $0.60 special dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales increased 51% YoY to $130.7M (including supportive services) for the year ended Dec 31, 2023.","Pre-tax operating income grew 96% to $83.6M; diluted EPS of $0.95 vs $0.46 in 2022.","Board declared special cash dividend of $0.60/share, up from $0.45 last year.","Fourth-quarter product sales surged to $115.7M, driven by $98M oral TPOXX delivery to U.S. SNS.","Over 25 countries ordered oral TPOXX in past two years; EU framework yielded $18M orders in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238314,"accession_number":"0001140361-24-003106","cik":1010086,"company_name":"SIGA TECHNOLOGIES INC","ticker":"SIGA","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SIGA appoints Diem Nguyen as CEO effective Jan 27, 2024; Phil Gomez retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diem Nguyen appointed CEO and board member effective Jan 27, 2024; Phil Gomez retires Jan 26.","Compensation includes $900K base salary, $450K 2024 bonus, $450K sign-on bonus, and equity grants valued at ~$3.15M.","Nguyen brings experience from Xalud Therapeutics (CEO), PPD (EVP biopharma), and Pfizer (global president, Americas Essential Health).","Employment agreement includes severance: 2x base salary for qualifying termination, 3x base plus bonus upon change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":339254953.4989293,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}